Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
COPD
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease…
- Trial name
- ZION (NCT06496620)
- Testing
- Biological: Solrikitug low dose, Biological: Solrikitug high dose
- Where
- 110 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Uniquity One (UNI)
Chronic Obstructive Pulmonary Disease
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.
This is a phase II clinical trial to evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT05987371
- Testing
- TQC3721 suspension for inhalation, Salbutamol sulfate inhalation aerosol
- Where
- 11 sites in China
- Volunteers
- 75 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
COPD
Study in Patients With COPD
The purpose of this study is to determine the efficacy and safety of the investigational drug in the treatment of COPD in comparison with a placebo.
- Trial name
- NCT00215449
- Testing
- Formoterol Fumarate
- Where
- 68 sites in United States
- Volunteers
- 690 people
- Sponsor
- Dey
Alpha 1-Antitrypsin Deficiency, Emphysema
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
The purpose of this study is to investigate the effect of alvelestat (an oral neutrophil elastase inhibitor) on blood and sputum biomarkers in patients with PiZZ, null or rare variant phenotype/genotype alpha-1 anti-trypsin…
- Conditions
- Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
- Trial name
- ASTRAEUS (NCT03636347)
- Testing
- Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 99 people
- Sponsor
- Mereo BioPharma
Pulmonary Disease, Chronic Obstructive
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
The purpose of this study is to evaluate the potential cardiovascular safety concerns and all-cause mortality described in the risk management plan for aclidinium bromide, through sequential, nested case-control studies for each…
- Trial name
- PASS (NCT03290287)
- Testing
- Aclidinium bromide, Other COPD medication
- Where
- United Kingdom
- Volunteers
- 26,839 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive…
- Trial name
- ECLIPSE (NCT00292552)
- Testing
- Novel endpoint determination
- Where
- 44 sites in United States, Bulgaria and 10 more
- Volunteers
- 2,747 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS
The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD…
- Trial name
- NCT04138758
- Testing
- Tiotropium bromide + Olodaterol, LABA/ICS
- Where
- United States
- Volunteers
- 42,953 people
- Sponsor
- Boehringer Ingelheim
COPD
Effect of Ensifentrine Treatment on CAT Score
The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with…
- Trial name
- NCT06460493
- Testing
- Ensifentrine 3 mg twice daily
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD).
- Trial name
- NCT02231320
- Testing
- Berodual® Respimat® - inhaler
- Volunteers
- 236 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
This study was designed to determine if the investigational drug is effective and safe in individuals with COPD (chronic pulmonary disease)
- Trial name
- NCT00103922
- Testing
- cilomilast
- Where
- 115 sites in United States
- Volunteers
- 600 people
- Sponsor
- GlaxoSmithKline
COPD
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.
- Trial name
- AER-01-002 (NCT06731959)
- Testing
- Flexlamose
- Volunteers
- 100 people
- Sponsor
- Aer Therapeutics
COPD
Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment
The overall objective is to asses the bronchodilator effect of once daily Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.) monotherapy delivered via Handihaler and tiotropium (q.d.)…
- Trial name
- NCT02988869
- Testing
- Tiotropium/Formoterol, Tiotropium, Formoterol
- Where
- Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
COPD, Pulmonary Hypertension
An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.
- Trial name
- NCT00677872
- Testing
- PRX-08066
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Asthma, COPD
Observational Study of Obstructive Lung Disease (NOVELTY)
The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis…
- Conditions
- Asthma, COPD, Chronic Obstructive Pulmonary Disease
- Trial name
- NOVELTY (NCT02760329)
- Testing
- Blood draw, Urine, Lung function measurements
- Where
- 331 sites in United States, Argentina and 17 more
- Volunteers
- 12,255 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each…
- Trial name
- NCT07016412
- Testing
- Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg
- Where
- 57 sites in United States
- Volunteers
- 497 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
COPD
Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe…
- Trial name
- GOLDEN7 (NCT02512302)
- Testing
- SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler®
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Sunovion Respiratory Development Inc.
Chronic Obstructive Pulmonary Disease, Bronchitis
Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate and compare the efficacy of arformoterol twice a day and tiotropium once a day (dosed sequentially) versus tiotropium once a day alone in subjects with Chronic Obstructive Pulmonary…
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Trial name
- NCT00424528
- Testing
- Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium
- Where
- 28 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients
This is an early feasibility study to investigate whether transcutaneous electrical stimulation applied to the abdominal wall muscles synchronous with voluntary exhalation can be used to support ventilation and affect…
- Trial name
- NCT02035228
- Testing
- Abdominal Stimulation - low / early, Abdominal stimulation - low/late, Abdominal Stimulation - low/full
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Liberate Medical
Chronic Obstructive Pulmonary Disease (COPD)
Phase IV O2 Consumption Study in COPD Patients.
A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.
- Trial name
- NCT02533505
- Testing
- Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
- Trial name
- NCT00274534
- Testing
- Tiotropium, Salmeterol
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.